| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2020-2023 |
| Base Year |
2024 |
| Forecast Period |
2025-2032 |
| Food Allergy Treatment Market Size 2024 |
USD 6,250 Million |
| Food Allergy Treatment Market, CAGR |
9.77% |
| Food Allergy Treatment Market Size 2032 |
USD 13,175 Million |
Market Overview:
The Food Allergy Treatment Market is projected to grow from USD 6,250 million in 2024 to USD 13,175 million by 2032, with a compound annual growth rate (CAGR) of 9.77% during the forecast period.
The food allergy treatment market is driven by a rising prevalence of food allergies, increasing awareness of allergy management, and growing demand for advanced therapies. Technological advancements in diagnostics and treatment, including personalized medicine and oral immunotherapy, are shaping the market’s growth. Regulatory approvals of new treatments, such as Palforzia for peanut allergies, and innovation in biologics like Xolair, are significantly enhancing patient outcomes. Furthermore, the surge in food allergy cases among children and toddlers is pushing the need for early diagnosis and effective treatments. The strategic collaborations between pharmaceutical companies and biotechnology firms are fueling the development of novel therapies. Additionally, increasing government support and reimbursement policies for allergy treatments encourage broader adoption of these therapies. These factors, combined with a focus on improving patient quality of life, are expected to accelerate market growth over the forecast period.
The food allergy treatment market exhibits strong regional variation, with North America leading at around 40% market share in 2024, driven by advanced healthcare infrastructure and regulatory approvals in the U.S. Europe follows with 30% market share, supported by a focus on pediatric care and adoption of innovative therapies. The Asia-Pacific region, holding 20% of the market, is emerging as a key growth area, fueled by rising food allergy cases and increasing healthcare awareness in countries like China, Japan, and India. The Rest of the World (RoW), including Latin America, the Middle East, and Africa, accounts for around 10% of the market, with gradual growth expected as healthcare access improves. Key players across these regions include Genentech, Stallergenes Greer, DBV Technologies, Intrommune Therapeutics, and Inimmune Corporation.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Insights:
- The food allergy treatment market is projected to grow from USD 6,250 million in 2024 to USD 13,175 million by 2032, with a compound annual growth rate (CAGR) of 9.77%.
- Rising prevalence of food allergies, especially among children, is a key market driver, increasing demand for advanced treatment options.
- Technological advancements in diagnostics and treatments, including oral immunotherapy (OIT) and biologics like Xolair, are enhancing patient outcomes.
- Regulatory approvals, such as Palforzia for peanut allergies, are fueling market growth, with innovations in personalized medicine shaping the industry.
- Strategic collaborations between pharmaceutical and biotech companies are accelerating the development of novel therapies for effective food allergy management.
- North America leads the market with 40% share in 2024, followed by Europe at 30%, Asia-Pacific at 20%, and the Rest of the World at 10%.
- Government support, favorable reimbursement policies, and increasing public awareness are driving broader adoption of allergy treatments globally.
Market Drivers:
Rising Prevalence of Food Allergies:
The increasing incidence of food allergies worldwide is a primary driver of the food allergy treatment market. A growing number of individuals, particularly children, are being diagnosed with food allergies, leading to heightened awareness and demand for effective treatments. DBV Technologies is actively investing in diagnostic tools and treatment options to address the rising prevalence of peanut and tree nut allergies. This rise is attributed to various factors, including changing dietary habits, environmental influences, and genetic predispositions.
Advancements in Allergy Diagnostics and Therapies:
Technological advancements in allergy diagnostics and treatment methods are key drivers of the market’s growth. The development of more precise and personalized diagnostic tools enables early detection and better management of food allergies. For instance, Aimmune Therapeutics has developed Palforzia, an FDA-approved oral immunotherapy treatment for peanut allergies, showcasing the potential for improved patient outcomes.
Government Support and Regulatory Approvals:
Supportive government initiatives and regulatory approvals are boosting the food allergy treatment market. For instance, the U.S. FDA’s approval of Palforzia has encouraged pharmaceutical companies to develop additional novel therapies and invest in innovation. Moreover, favorable reimbursement policies for food allergy treatments help reduce the financial burden on patients, making these therapies more accessible.
Strategic Collaborations and Partnerships:
Collaborations between pharmaceutical companies, biotechnology firms, and research institutions play a crucial role in driving innovation within the food allergy treatment market. The partnership between Mitsubishi Gas Chemical Company and Alerje, Inc. has focused on creating personalized care solutions, including advanced epinephrine auto-injectors. These collaborations accelerate the commercialization of innovative products and contribute significantly to market expansion.
Market Trends:
Growth in Oral Immunotherapy (OIT):
One of the current trends in the food allergy treatment market is the increasing adoption of oral immunotherapy (OIT) for managing allergies, particularly in children. OIT works by gradually exposing patients to small amounts of allergens, aiming to desensitize the immune system. For instance, Aimmune Therapeutics’ Palforzia, approved for peanut allergies, has demonstrated significant effectiveness in reducing severe allergic reactions. The growing preference for OIT among healthcare providers and patients reflects its promising potential in managing food allergies more effectively over time.
Advancements in Biologic Treatments:
The development and approval of biologic treatments are revolutionizing the food allergy treatment landscape. Biologics, such as Xolair (omalizumab), have shown significant efficacy in treating severe allergic reactions and conditions like anaphylaxis. For instance, Novartis and Genentech’s Xolair targets specific immune system components to provide a more targeted and long-lasting approach for food allergy management. As more biologic therapies enter the market, they are expected to offer enhanced patient outcomes, particularly for individuals with complex or life-threatening food allergies.
Personalized Allergy Treatments:
Another emerging trend is the shift towards personalized allergy treatments, driven by advancements in precision medicine. Healthcare providers are increasingly using personalized diagnostic tools and tailored therapies to address individual patients’ specific allergic profiles. Thermo Fisher Scientific has introduced component-resolved diagnostics to deliver more precise and personalized allergy treatment plans. Personalized treatments offer greater efficacy and safety, contributing to better quality of life for patients.
Increased Focus on Pediatric Allergy Treatment:
The rising incidence of food allergies in children has spurred increased focus on pediatric allergy treatments. Pharmaceutical companies are prioritizing the development of therapies suitable for young patients, addressing both safety and efficacy concerns. The approval of Palforzia by Aimmune Therapeutics for use in toddlers reflects the growing commitment to meeting the unique needs of pediatric patients. This focus further drives innovation and growth in the food allergy treatment market.
Market Challenges Analysis:
High Cost of Treatment and Limited Accessibility:
One of the major challenges facing the food allergy treatment market is the high cost of innovative therapies and limited accessibility, particularly in low- and middle-income regions. Advanced treatments, such as biologics and oral immunotherapy (OIT), often come with a significant financial burden for patients and healthcare systems. While treatments like Palforzia and Xolair have demonstrated effectiveness in managing food allergies, their high costs may prevent widespread adoption, especially in countries with inadequate healthcare infrastructure or limited insurance coverage. For instance, “The list price of Palforzia is set at $890 per month. This comes out to more than $10,000 per year”.This creates a disparity in access to effective allergy treatments, limiting their availability to those who can afford them. Additionally, in regions where healthcare reimbursement policies are less favorable, patients may face difficulties in obtaining financial support for these high-cost treatments, further restricting their accessibility.
Complexity of Regulatory Approvals and Long Development Cycles:
Another significant challenge in the food allergy treatment market is the complexity of regulatory approval processes and the long development cycles required for new therapies. Developing novel treatments for food allergies involves rigorous clinical trials to ensure safety and efficacy, particularly given the life-threatening nature of severe allergic reactions. Biologics, immunotherapies, and personalized treatments must meet stringent regulatory standards before receiving approval, often leading to extended timelines. Delays in regulatory approvals and the high costs associated with clinical trials pose obstacles for companies trying to bring innovative treatments to market. Additionally, navigating the diverse regulatory frameworks across different countries can further complicate global market entry, limiting the availability of treatments in certain regions. This regulatory complexity, combined with the inherent challenges of developing safe and effective allergy treatments, continues to be a significant barrier to the rapid commercialization of new therapies in the food allergy treatment market.
Market Opportunities:
The food allergy treatment market presents significant growth opportunities, particularly with the increasing demand for innovative therapies and the rising prevalence of food allergies globally. Advances in biotechnology, such as the development of biologic drugs and immunotherapies, offer new avenues for effective treatments. As personalized medicine gains momentum, there is an opportunity for pharmaceutical companies to develop tailored solutions that address individual allergic profiles, improving patient outcomes. The expansion of oral immunotherapy (OIT) treatments, especially for pediatric populations, further provides a growing market segment where companies can develop age-appropriate formulations and expand product portfolios.
Additionally, emerging markets present untapped potential for growth. As awareness of food allergies increases in developing regions, the demand for affordable and accessible treatments is expected to rise. Companies that focus on improving affordability and broadening access to treatment in these regions will have the opportunity to capture a significant share of the global market. Furthermore, strategic partnerships between pharmaceutical companies, biotechnology firms, and healthcare providers can accelerate the development and commercialization of innovative treatments. Collaboration can also enable access to new technologies, resources, and market channels, creating an environment ripe for market expansion. As food allergies become a growing global health concern, companies that leverage these opportunities can play a critical role in shaping the future of allergy care and treatment.
Market Segmentation Analysis:
By Allergen Type
The food allergy treatment market is segmented by allergen type, including peanuts, milk, eggs, tree nuts, and others. Peanut allergies represent the largest segment, driven by the high prevalence of peanut allergy, especially in children. Treatments like Palforzia cater specifically to this market, fueling its growth. Other allergens like milk and tree nuts also see growing demand for targeted treatments.
By Drug Type
By drug type, the market includes biologics, antihistamines, epinephrine, and immunotherapies. Biologics, such as Xolair, are gaining traction due to their targeted action on the immune system, offering long-term allergy management. Immunotherapies, including oral and sublingual formulations, are growing in popularity due to their potential for desensitizing patients to allergens over time.
By End Use
End-use segments in the food allergy treatment market include hospitals, clinics, and home settings. Hospitals and clinics remain the dominant segment due to the need for specialized care in administering biologics and immunotherapy treatments. However, the homecare segment is expanding as oral immunotherapy and epinephrine autoinjectors become more accessible for at-home use.
Segments:
Based on Allergen Type
- Peanuts
- Tree Nuts
- Dairy Products
- Poultry Product
- Shellfish
- Wheat
- Soy
- Others
Based on Drug Type
- Epinephrine
- Immunotherapy
Based on Route of Administration
Based on End-Use
- Hospital Pharmacies
- Retail Pharmacies
- Others
Based on the Geography:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America
North America dominates the food allergy treatment market, holding the largest market share, accounting for 40% in 2024. This leadership is driven by a high prevalence of food allergies, particularly among children, and a well-established healthcare infrastructure that supports the adoption of advanced treatments. The U.S. contributes significantly to the region’s growth due to regulatory approvals for innovative therapies, such as Palforzia for peanut allergies and Xolair for severe allergic reactions. Additionally, increasing awareness, early diagnosis, and a rise in research and development activities are further driving market expansion. The presence of major pharmaceutical and biotechnology companies also ensures the availability of cutting-edge treatment options, contributing to North America’s strong market position.
Europe
Europe is the second-largest market for food allergy treatments, with a market share of 30% in 2024. The region’s growth is fueled by an increasing prevalence of food allergies and a growing focus on pediatric care. The regulatory approval of new treatments and the rising adoption of oral immunotherapy (OIT) are contributing to market expansion in key countries such as the UK, Germany, and France. Europe’s stringent regulatory frameworks ensure high standards for allergy treatment, which in turn encourages the development of safe and effective therapies. Moreover, government initiatives to raise awareness about food allergies and improve patient access to treatments are further supporting market growth.
Asia-Pacific
Asia-Pacific is an emerging market for food allergy treatment, capturing 20% of the global market share in 2024. The region’s growth is driven by an increasing incidence of food allergies, particularly in urban areas, due to changing dietary habits and environmental factors. Countries such as China, Japan, and India are witnessing a rise in awareness and diagnosis of food allergies, leading to greater demand for effective treatments. While the market is still developing, the growing focus on healthcare infrastructure and the adoption of advanced therapies are expected to boost market growth. Additionally, Asia-Pacific offers significant opportunities for pharmaceutical companies to expand their presence through strategic collaborations and partnerships.
Rest of the World (RoW)
The Rest of the World, which includes regions such as Latin America, the Middle East, and Africa, holds a smaller market share, 10% in 2024. However, these regions present untapped potential due to the increasing awareness of food allergies and a growing need for accessible treatments. Limited healthcare infrastructure and high treatment costs have historically hindered market growth in these regions. However, government initiatives and international collaborations are gradually improving access to advanced allergy treatments. Over time, the food allergy treatment market in these regions is expected to witness moderate growth as awareness and healthcare investments increase.
Key Player Analysis:
- Inimmune Corporation
- Alerje, Inc.
- Genentech
- Camallergy
- HAL Allergy
- Cour Pharmaceuticals Development Company, Inc.
- Prota Therapeutics Pty. Ltd.
- Stallergenes Greer
- DBV Technologies
- Intrommune Therapeutics
- Siolta Therapeutics
- NemaGen Discoveries
Competitive Analysis:
The food allergy treatment market is highly competitive, with leading players such as Genentech, Stallergenes Greer, DBV Technologies, Inimmune Corporation, Intrommune Therapeutics, Alerje, Inc., HAL Allergy, Camallergy, Prota Therapeutics Pty. Ltd., Siolta Therapeutics, Cour Pharmaceuticals Development Company, Inc., and NemaGen Discoveries actively driving innovation. These companies are investing in the development of novel therapies, such as biologics, oral immunotherapy (OIT), and personalized treatments to address the growing prevalence of food allergies. Genentech and Stallergenes Greer have gained notable market positions through the approval of products like Xolair and Palforzia, respectively. Intrommune Therapeutics and Inimmune Corporation are focusing on cutting-edge immunotherapies, while DBV Technologies continues to advance its epicutaneous immunotherapy solutions. Companies are also forming strategic partnerships and expanding their research pipelines to enhance their market share. With increasing regulatory approvals and advancements in treatment options, the competitive landscape in the food allergy treatment market is expected to remain dynamic and growth-focused.
Recent Developments:
- In January 2024, Inimmune Corporation announced a collaboration with Intrommune Therapeutics to develop a novel oral mucosal immunotherapy (OMIT) for treating peanut allergies. The partnership combines Intrommune’s OMIT with Inimmune’s clinical-stage proprietary immunotherapy, designed to accelerate desensitization to allergens.
- In February 2024, the U.S. FDA approved Xolair, developed by Genentech, as the first treatment for severe allergies. This injection is approved for use in both adults and children aged one year and older.
- In July 2024, Stallergenes Greer received U.S. FDA approval for Palforzia (Peanut Allergen Powder) to treat peanut allergies in toddlers aged 1-3 years. This approval marks the first oral immunotherapy for reducing allergic reactions, including anaphylaxis, from accidental peanut exposure.
- In September 2024, Mitsubishi Gas Chemical Company announced a strategic partnership with Alerje, Inc. The partnership aims to transform global allergy diagnosis and treatment by creating personalized allergy care solutions to improve patient outcomes and overall quality of life.
Market Concentration & Characteristics:
The food allergy treatment market is moderately concentrated, with a few key players dominating the global landscape. Companies like Genentech, Stallergenes Greer, DBV Technologies, and Intrommune Therapeutics have established significant market presence through the development of innovative therapies and strategic partnerships. These leading players are actively engaged in research and development, driving innovation in biologics, oral immunotherapy (OIT), and personalized treatments. Market characteristics include high entry barriers due to the complexity of regulatory approvals and the substantial investments required for clinical trials and product development. Additionally, the market is highly competitive, with companies focusing on expanding their product portfolios and gaining regulatory approvals to strengthen their positions. The growing prevalence of food allergies, particularly among children, and the increasing demand for advanced, targeted therapies are shaping the market. Overall, the food allergy treatment market is expected to grow steadily, driven by technological advancements and strategic collaborations.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on Allergen Type, Drug Type, Route of AdministartionEnd-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- The food allergy treatment market is expected to grow significantly, driven by rising food allergy cases worldwide.
- Increased demand for advanced therapies like oral immunotherapy and biologics will enhance treatment options.
- Technological advancements in diagnostics will lead to earlier and more accurate detection of food allergies.
- Regulatory approvals of novel treatments will continue to boost market expansion and innovation.
- Personalized medicine will play a crucial role in improving patient outcomes and tailoring allergy treatments.
- Strategic collaborations between pharmaceutical companies and biotech firms will accelerate the development of new therapies.
- North America will remain the leading region, while Asia-Pacific will emerge as a key growth market.
- Growing awareness of food allergies among the public will further drive demand for effective treatments.
- Government initiatives and supportive reimbursement policies will encourage broader access to allergy treatments.
- Investment in research and development will continue to push the boundaries of food allergy treatment solutions.
